Posted by Michael Wonder on 03 Nov 2022
Rhythm Pharmaceuticals announces setmelanotide granted breakthrough therapy designation for hypothalamic obesity by the US FDA
1 November 2022 - Rhythm Pharmaceuticals today announced that setmelanotide received breakthrough therapy designation from the US FDA for the treatment of hypothalamic obesity.
Breakthrough therapy designation was granted based on results from a Phase 2, 16 week clinical study of setmelanotide.
